Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag S/Adr (OP:BAYRY)

13.54 -0.07 (-0.51%)
Streaming Delayed Price Updated: 10:42 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag S/Adr

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
From Bayer
Via Business Wire
News headline image
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
From Bayer
Via Business Wire
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗
Via Stocktwits
News headline image
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset
The CBOE Volatility Index (VIX), often hailed as the stock market’s “fear gauge,” surged past the critical 20.00 threshold on January 20, 2026, marking a significant shift in investor sentiment as the... 
Via MarketMinute
Topics Economy Government Stocks
News headline image
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
From Bayer
Via Business Wire
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Bayer Accelerates Pharma Growth on High-Value Portfolio
From Bayer
Via Business Wire
News headline image
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
From Bayer
Via Business Wire
News headline image
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
From Bayer
Via Business Wire
News headline image
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
From Bayer
Via Business Wire
News headline image
Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program
As the 2026 calendar year begins, the United States agricultural sector finds itself at a critical policy crossroads. On one hand, the U.S. Department of Agriculture (USDA) has just finalized the... 
Via MarketMinute
Topics Economy Energy
News headline image
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
From Bayer
Via Business Wire
News headline image
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
From Bayer
Via Business Wire
News headline image
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
From Bayer
Via Business Wire
News headline image
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer. 
Via Benzinga
News headline image
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗
 
Via Benzinga
News headline image
Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗
Daré Bioscience (DARE) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗
Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company's upgraded 2025 guidance. 
Via Benzinga
News headline image
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
From Bayer
Via Business Wire
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.